News & Updates

The inclusion of nonlinear relationships for diameter and thickness, clinical characteristics such as sex and tumour location, and differentiation can improve the staging systems of cutaneous squamous cell carcinoma (cSCC), suggests a recent study.

Biologic treatments are effective in the treatment of mucous membrane pemphigoid (MMP), with a good safety profile, except for rituximab, a study has found. However, randomized clinical trials with long-term follow-up are warranted to confirm the safety and efficacy of these agents in MMP patients.

The pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation is well tolerated and demonstrates a dose-response effect in the treatment of patients with chronic hand eczema, according to the results of a phase IIb trial.

Use of photodynamic therapy, 5-fluorouracil, or imiquimod is not as effective as electrodessication and cryotherapy, in combination with curettage, in the treatment of squamous cell carcinoma in situ (SCCIS) and squamous cell carcinoma (SCC), results of a study have shown.

New drug applications approved by US FDA as of 16 - 30 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Wearing filtering facepiece 3 (FFP3) masks for more than the recommended 1-hour duration can lead to facial injuries, a new study has found.

The C5 and leukotriene B4 inhibitor nomacopan helps suppress acute flares in older patients with bullous pemphigoid, according to the results of a phase IIa study.

A compact device that incorporates high-resolution millimetre-wave imaging (HR-MMWI) can diagnose malignant skin lesions as accurately as clinical examination and other detection techniques, potentially cutting the number of unnecessary biopsies in half, as reported in a study.